Whether switching from low-molecular-weight heparin to direct oral anticoagulants (DOACs) in cancer-associated thrombosis patients is safe and effective is unknown. Here, the authors show that switching to DOACs reduced venous thromboembolism and mortality without increasing bleeding.
- Wei Kang
- Caige Huang
- Esther W. Chan
